ASCO 2022: Combinations Containing Tisotumab Vedotin Show Promise in Metastatic/Recurrent Cervical Cancer
The therapy was tested in combination with pembrolizumab and carboplatin
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.